NPS Pharmaceuticals Inc (NPSP) Financial Statements (2026 and earlier)
Company Profile
| Business Address |
550 HILLS DRIVE BEDMINSTER, NJ 07921 |
| State of Incorp. | DE |
| Fiscal Year End | December 31 |
| Industry (SIC) | 2836 - Biological Products, Except Diagnostic Substances (benchmarking) |
| More info | Complete Financial Analysis Financial Benchmarking |
Balance Sheet (Statement of Financial Position) ($ in thousands)
| 12/31/2014 | 12/31/2013 | 12/31/2012 | |||
|---|---|---|---|---|---|
| ASSETS | |||||
| Current Assets | |||||
| Cash, cash equivalents, and short-term investments | 180,474 | 100,715 | |||
| Cash and cash equivalent | 51,204 | 17,471 | |||
| Short-term investments | 129,270 | 83,244 | |||
| Receivables | 41,242 | 30,276 | |||
| Inventory, net of allowances, customer advances and progress billings | 30,035 | ✕ | |||
| Inventory | 30,035 | ||||
| Prepaid expense | 5,621 | ✕ | |||
| Other current assets | 1,380 | ✕ | |||
| Prepaid expense and other current assets | ✕ | ✕ | 6,060 | ||
| Total current assets: | 258,752 | 137,051 | |||
| Noncurrent Assets | |||||
| Property, plant and equipment | 4,402 | 4,193 | |||
| Intangible assets, net (including goodwill) | 28,730 | 9,429 | |||
| Goodwill | 9,429 | 9,429 | |||
| Intangible assets, net (excluding goodwill) | 19,301 | ||||
| Other noncurrent assets | ✕ | ||||
| Other undisclosed noncurrent assets | 338 | 436 | |||
| Total noncurrent assets: | 33,470 | 14,058 | |||
| TOTAL ASSETS: | 292,222 | 151,109 | |||
| LIABILITIES AND EQUITY | |||||
| Liabilities | |||||
| Current Liabilities | |||||
| Accounts payable and accrued liabilities | 29,576 | 17,653 | |||
| Interest and dividends payable | 1,620 | 3,983 | |||
| Accounts payable | 10,919 | 4,373 | |||
| Accrued liabilities | 17,037 | 9,297 | |||
| Debt | 8,752 | 6,278 | |||
| Other undisclosed current liabilities | 20,086 | 5,636 | |||
| Total current liabilities: | 58,414 | 29,567 | |||
| Noncurrent Liabilities | |||||
| Long-term debt and lease obligation | 123,635 | 169,569 | |||
| Long-term debt, excluding current maturities | 123,635 | 169,569 | |||
| Liabilities, other than long-term debt | 5,283 | 6,614 | |||
| Other liabilities | 5,283 | 6,614 | |||
| Total noncurrent liabilities: | 128,918 | 176,183 | |||
| Total liabilities: | 187,332 | 205,750 | |||
| Equity | |||||
| Equity, attributable to parent | 104,890 | (54,641) | |||
| Common stock | 103 | 87 | |||
| Additional paid in capital | 1,127,420 | 954,452 | |||
| Accumulated other comprehensive income (loss) | 56 | 5 | |||
| Accumulated deficit | (1,022,689) | (1,009,185) | |||
| Total equity: | 104,890 | (54,641) | |||
| TOTAL LIABILITIES AND EQUITY: | 292,222 | 151,109 | |||
Income Statement (P&L) ($ in thousands)
| 12/31/2014 | 12/31/2013 | 12/31/2012 | ||
|---|---|---|---|---|
| Revenues | 155,592 | 130,644 | ||
| Revenue, net | 155,556 | 130,644 | ||
| Cost of revenue (Cost of Product and Service Sold) | (3,596) | |||
| Gross profit: | 151,996 | 130,644 | ||
| Operating expenses | (153,491) | (131,768) | ||
| Operating income (loss): | (1,495) | (1,124) | ||
| Nonoperating expense | (11,827) | (17,611) | ||
| Interest and debt expense | (11,938) | (18,198) | ||
| Other undisclosed income from continuing operations before equity method investments, income taxes | 11,938 | 18,198 | ||
| Loss from continuing operations before income taxes: | (13,322) | (18,735) | ||
| Income tax expense | (182) | |||
| Loss from continuing operations: | (13,504) | (18,735) | ||
| Loss before gain (loss) on sale of properties: | (13,504) | (18,735) | ||
| Net loss available to common stockholders, diluted: | (13,504) | (18,735) | ||
Comprehensive Income ($ in thousands)
| 12/31/2014 | 12/31/2013 | 12/31/2012 | ||
|---|---|---|---|---|
| Net loss: | (13,504) | (18,735) | ||
| Other comprehensive income (loss) | 51 | |||
| Comprehensive loss: | (13,453) | (18,735) | ||
| Other undisclosed comprehensive income, net of tax, attributable to parent | 101 | |||
| Comprehensive loss, net of tax, attributable to parent: | (13,453) | (18,634) | ||
Statements Sources
The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.